Buscar
Korro Bio Inc
KRROAñadir a la lista de seguimiento
12.050USD
-0.840-6.52%
Cierre 05/08, 16:00（ET）Cotizaciones retrasadas 15 min
173.79MCap. mercado
PérdidaP/E TTM
Más Datos de Korro Bio Inc Compañía
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Información de Korro Bio Inc
Símbolo de cotizaciónKRRO
Nombre de la empresaKorro Bio Inc
Fecha de salida a bolsaOct 03, 2019
Director ejecutivoDr. Ram Aiyar, Ph.D.
Número de empleados104
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 03
DirecciónOne Kendall Square. Building 600-700
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139
Teléfono16174681999
Sitio Webhttps://www.korrobio.com/
Símbolo de cotizaciónKRRO
Fecha de salida a bolsaOct 03, 2019
Director ejecutivoDr. Ram Aiyar, Ph.D.
Ejecutivos de Korro Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
6.39M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: hace 8 horas
Actualizado: hace 8 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Lynx1 Capital Advisors LLC
10.67%
New Enterprise Associates (NEA)
9.00%
Atlas Venture
7.88%
VR Adviser, LLC
7.00%
Point72 Asset Management, L.P.
5.66%
Otro
59.79%
Accionistas
Accionistas
Proporción
Lynx1 Capital Advisors LLC
10.67%
New Enterprise Associates (NEA)
9.00%
Atlas Venture
7.88%
VR Adviser, LLC
7.00%
Point72 Asset Management, L.P.
5.66%
Otro
59.79%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.98%
Venture Capital
24.28%
Hedge Fund
13.54%
Investment Advisor/Hedge Fund
4.01%
Research Firm
3.19%
Individual Investor
0.56%
Bank and Trust
0.07%
Pension Fund
0.05%
Otro
17.33%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
215
11.84M
86.30%
+782.64K
2025Q4
193
11.05M
117.36%
+1.14M
2025Q3
186
9.33M
99.33%
-1.07M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Lynx1 Capital Advisors LLC
677.91K
4.7%
+677.91K
--
Dec 31, 2025
New Enterprise Associates (NEA)
1.30M
9%
+207.10K
+18.99%
Mar 10, 2026
Atlas Venture
1.14M
7.88%
--
--
Dec 31, 2025
VR Adviser, LLC
1.01M
7%
+1.01M
--
Mar 10, 2026
Point72 Asset Management, L.P.
816.88K
5.66%
+816.88K
--
Mar 10, 2026
Nantahala Capital Management, LLC
600.00K
4.16%
+600.00K
--
Dec 31, 2025
Vanguard Investments Australia Ltd.
489.64K
3.39%
+489.64K
--
Dec 31, 2025
The Vanguard Group, Inc.
489.64K
3.39%
+93.98K
+23.75%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
419.30K
2.91%
+10.58K
+2.59%
Dec 31, 2025
TCG Crossover Management, LLC
416.30K
2.89%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.05%
Avantis US Small Cap Equity ETF
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0%
SPDR Portfolio MSCI Global Stock Market ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
iShares Russell 3000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
